Latest News and Press Releases
Want to stay updated on the latest news?
Featured Releases
-
COSTA MESA, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Bastion, today announced the appointment of Jody Sowa as Managing Director, Public Relations in the United States, strengthening the company’s...
Read More -
As the holiday season intensifies feelings of loss, Dianetics provides an avenue for relief and renewed joy for those coping with grief.
Read More
-
COSTA MESA, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Bastion, today announced the appointment of Jody Sowa as Managing Director, Public Relations in the United States, strengthening the company’s...
-
Data demonstrates the significant and sustained tumor regression achieved by the CAPTN-3 platform across two distinct tri-specific antibodies, IM1240 and IM1305, targeting different tumor antigens ...
-
As the holiday season intensifies feelings of loss, Dianetics provides an avenue for relief and renewed joy for those coping with grief.
-
VANCOUVER, British Columbia, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Nevada Lithium Resources Inc. (TSXV: NVLH; OTCQB: NVLHF; FSE: 87K) (“Nevada Lithium” or the “Company”) is pleased to announce that it...
-
AmpliTech Group Announces Successful Rights Offering at $4 Per Unit, Over-subscriptions Received
-
Fast Track designation supported by positive results from the KT-621 BroADen Phase 1b atopic dermatitis (AD) patient trial KT-621 BROADEN2 Phase 2b AD trial ongoing, with data expected to be...
-
iHerb Chief Executive Officer, Emun Zabihi, has been named to The CEO Forum Group’s “Top 10 CEOs Transforming Healthcare” list for 2025.
-
EVgo Appoints Keefer Lehner as Chief Financial Officer Effective January 12, 2026 Seasoned Executive Brings Finance and Operations Experience to Support High Growth Build-Out to Meet Charging Demand...
-
TORONTO, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), a global lifestyle and consumer packaged goods company at the forefront of the cannabis, beverage...
-
The results show, for the first time, that targeting a-syn pathology with an active immunotherapy could potentially slow the rate of progression of PD.